Marksans Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 0.90 per equity share.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.7 pts more than Nifty Microcap 250 and 15.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma's Board approved FY 2025-26 standalone revenue of Rs. 14,450 million (up 17% YoY) and consolidated revenue of Rs. 29,509 million (up 13% YoY). Standalone PAT grew 60% to Rs. 3,007 million while consolidated PAT rose 10% to Rs. 4,201 million. The Board recommended a final dividend of Rs. 0.90 per equity share (90% on face value of Re. 1) for FY 2025-26, subject to shareholder approval at the upcoming AGM. The statutory auditors gave an unmodified opinion on both standalone and consolidated financial results. Two new wholly-owned subsidiaries were formed in Europe and Canada during the year.
The strong 60% jump in standalone PAT and healthy revenue growth reflect solid operational performance. The recommended 90% dividend payout signals confidence in sustained profitability and cash generation, which could positively influence investor sentiment.